Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06679270 · ClinicalTrials.gov registry record · Phase 3
Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
A Phase 3 study of Familial Partial Lipodystrophy, sponsored by Amryt Pharma.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 24
- Enrollment target
- 7
- Study locations
NCT06679270 is a Phase 3 study of Familial Partial Lipodystrophy that is actively recruiting participants, run by Amryt Pharma. The registered enrollment target is 24 participants. The trial reports 7 study locations across 7 states.
The verdict
NCT06679270, a Phase 3 study of Familial Partial Lipodystrophy, is actively recruiting participants, sponsored by Amryt Pharma.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 24 participants
- Enrollment target
- 7
- Study locations
Study Summary
This Phase 3 study is an Open Label Extension of the APG-20 Study To Evaluate the Long-term Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with Partial Lipodystrophy
Conditions Studied
Interventions
- DRUG Metreleptin
Study Locations (7)
Alabama
- University of Alabama - Birmingham
Florida
- Flourish Research - Boca Raton
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- University of Michigan - Ann Arbour
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Texas
- UT Southwestern Medical Center - Dallas
Wisconsin
- The Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-10-14 |
| Est. Completion | 2028-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06679270
The ClinicalTrials.gov registry entry for NCT06679270 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amryt Pharma, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Familial Partial Lipodystrophy appearing as the primary indexed condition, and to 1 intervention - of which Metreleptin is the first listed.
NCT06679270 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Alabama, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06679270 about?
NCT06679270 is a clinical study titled "Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy". This Phase 3 study is an Open Label Extension of the APG-20 Study To Evaluate the Long-term Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with Partial Lipodystrophy
What is the current status of trial NCT06679270?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 24 participants. The study started on 2024-10-14. Estimated completion is 2028-12.
What conditions does trial NCT06679270 study?
This clinical trial studies the following conditions: Familial Partial Lipodystrophy.
What interventions are being tested in trial NCT06679270?
The interventions under investigation include: Metreleptin (DRUG).
Who is sponsoring clinical trial NCT06679270?
This trial is sponsored by Amryt Pharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06679270 being conducted?
This trial has 7 study locations across Alabama, Florida, Massachusetts, Michigan, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Familial Partial Lipodystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.